Biotech Acquisition Company announced that it expects to receive $24.3 million in funding from Bristol-Myers Squibb Company, Deerfield Management Company, L.P., Pfizer Venture Investments LLC, Osage University Partners, MPM Asset Management, L.L.C. and other investors

Biotech Acquisition Company announced that it entered into agreement with investors to purchase 2,430,000 Class A ordinary common shares at an issue price of $10 per each, at a par value of 0.0001 per share for gross proceeds of $24,300,000 on November 8, 2021. The transaction includes institutional investors, including Deerfield Management Company, L.P., Pfizer Venture Investments LLC, Bristol-Myers Squibb Company, MPM Asset Management, L.L.C, Osage University Partners and other returning investors. The securities are issued pursuant to exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D. The closing is subjected to other customary closing conditions.

The transaction is approved by board of directors of the company. The completion of the transaction is subject, among other things, to shareholder approval.